RxDoctor Payments Data

James Beattie, MD

Cardiovascular Disease · Princeton, NJNPI 1922037704

Payments from drug & device makers

$900in general payments, 2019–2025

Across 12 payments — averaging $75.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$450
  • Abbott$182
  • AstraZeneca$114
  • Medtronic$58
  • Pfizer$51
  • Preventice Services, LLC$19
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$507,246
Medicare patients
2,176
Services billed
6,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban430$570,116
XareltoRivaroxaban189$250,908
EntrestoSacubitril/Valsartan43$74,448
JardianceEmpagliflozin33$50,412
Praluent PenAlirocumab49$49,641
Repatha SureclickEvolocumab26$29,889
NexlizetBempedoic Acid/Ezetimibe22$17,474
Metoprolol Succinate828$14,845
Repatha SyringeEvolocumab13$13,474
Ranolazine ErRanolazine51$10,107
Rosuvastatin Calcium576$9,996
Olmesartan Medoxomil252$7,667
Diltiazem 24hr Er (Cd)Diltiazem Hcl165$7,382
Dabigatran EtexilateDabigatran Etexilate Mesylate24$7,243
Atorvastatin Calcium543$7,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$570,116430 claims
Johnson & JohnsonXarelto$13$250,908189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →